Frédéric Amant

42.9k total citations · 10 hit papers
554 papers, 21.9k citations indexed

About

Frédéric Amant is a scholar working on Obstetrics and Gynecology, Oncology and Reproductive Medicine. According to data from OpenAlex, Frédéric Amant has authored 554 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Obstetrics and Gynecology, 230 papers in Oncology and 199 papers in Reproductive Medicine. Recurrent topics in Frédéric Amant's work include Endometrial and Cervical Cancer Treatments (186 papers), Ovarian cancer diagnosis and treatment (169 papers) and Cancer Risks and Factors (150 papers). Frédéric Amant is often cited by papers focused on Endometrial and Cervical Cancer Treatments (186 papers), Ovarian cancer diagnosis and treatment (169 papers) and Cancer Risks and Factors (150 papers). Frédéric Amant collaborates with scholars based in Belgium, Netherlands and United States. Frédéric Amant's co-authors include Ignace Vergote, Patrick Neven, D. Timmerman, Kristel Van Calsteren, Philippe Moerman, Carien L. Creutzberg, Karin Leunen, Mansoor Raza Mirza, Erik Van Limbergen and Toon Van Gorp and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Frédéric Amant

528 papers receiving 21.4k citations

Hit Papers

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC... 2005 2026 2012 2019 2010 2014 2005 2015 2016 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
    2010 1.7k citations Ignace Vergote, Frédéric Amant et al. profile →
  2. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
    2014 1.2k citations Frédéric Amant et al. profile →
  3. Endometrial cancer
    2005 1.2k citations Frédéric Amant, Philippe Moerman et al. profile →
  4. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
    2015 558 citations Carien L. Creutzberg, Frédéric Amant et al. International Journal of Gynecological Cancer profile →
  5. Tumour hypoxia causes DNA hypermethylation by reducing TET activity
    2016 459 citations Frédéric Amant, Diether Lambrechts et al. profile →
  6. ESHRE guideline: female fertility preservation†
    2020 406 citations Frédéric Amant et al. profile →
  7. Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability
    2017 304 citations Frédéric Amant et al. profile →
  8. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
    2020 281 citations Frédéric Amant, M Halaška et al. profile →
  9. Cancer of the corpus uteri
    2018 277 citations Frédéric Amant, Carien L. Creutzberg et al. profile →
  10. Cancer of the corpus uteri: 2021 update
    2021 174 citations Frédéric Amant, Carien L. Creutzberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frédéric Amant Belgium 66 9.0k 8.7k 7.2k 3.7k 3.5k 554 21.9k
David M. Gershenson United States 76 12.0k 1.3× 8.2k 1.0× 5.2k 0.7× 4.2k 1.1× 5.9k 1.7× 406 21.6k
David G. Mutch United States 68 6.9k 0.8× 9.4k 1.1× 4.3k 0.6× 4.0k 1.1× 4.6k 1.3× 449 19.1k
Karen H. Lu United States 72 8.3k 0.9× 5.3k 0.6× 6.8k 0.9× 7.4k 2.0× 2.1k 0.6× 427 21.6k
Robert L. Coleman United States 72 9.5k 1.1× 5.7k 0.7× 7.7k 1.1× 7.7k 2.1× 4.1k 1.2× 690 23.3k
Hys Ngan Hong Kong 68 4.1k 0.5× 4.3k 0.5× 4.1k 0.6× 6.9k 1.9× 3.8k 1.1× 521 21.5k
Michael Friedländer Australia 73 9.8k 1.1× 2.6k 0.3× 15.7k 2.2× 7.5k 2.0× 3.2k 0.9× 493 27.5k
Jonathan S. Berek United States 67 8.1k 0.9× 7.4k 0.9× 4.3k 0.6× 1.9k 0.5× 4.7k 1.3× 297 16.6k
Ursula A. Matulonis United States 77 8.2k 0.9× 2.0k 0.2× 13.4k 1.8× 7.9k 2.1× 1.6k 0.5× 443 23.1k
Stephen C. Rubin United States 62 6.4k 0.7× 2.6k 0.3× 6.0k 0.8× 2.5k 0.7× 3.6k 1.0× 276 15.3k
Douglas A. Levine United States 70 7.3k 0.8× 4.5k 0.5× 6.7k 0.9× 9.3k 2.5× 3.5k 1.0× 256 22.4k

Countries citing papers authored by Frédéric Amant

Since Specialization
Citations

This map shows the geographic impact of Frédéric Amant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Amant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Amant more than expected).

Fields of papers citing papers by Frédéric Amant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Amant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Amant. The network helps show where Frédéric Amant may publish in the future.

Co-authorship network of co-authors of Frédéric Amant

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Amant. A scholar is included among the top collaborators of Frédéric Amant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Amant. Frédéric Amant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Storgaard, Lone, et al.. (2025). Cervical cancer in pregnancy. Seminars in Perinatology. 49(2). 152038–152038. 1 indexed citations
2.
Amant, Frédéric, et al.. (2024). Long‐term outcomes of children after prenatal exposure to maternal cancer and its treatment. Acta Obstetricia Et Gynecologica Scandinavica. 103(4). 757–760. 3 indexed citations
3.
Tjan‐Heijnen, Vivianne C. G., Joosje H. Heimovaara, Liesbeth Lenaerts, et al.. (2024). Prenatal cell-free DNA testing of women with pregnancy-associated cancer: a retrospective cross-sectional study. The Lancet Regional Health - Europe. 45. 101024–101024. 3 indexed citations
4.
Heimovaara, Joosje H., Kristel Van Calsteren, Christianne Lok, et al.. (2024). Results of an international survey on the current organization of care for pregnant women with cancer. Acta Obstetricia Et Gynecologica Scandinavica. 103(4). 751–756. 2 indexed citations
5.
Vandecaveye, Vincent, Raphaëla C. Dresen, Els Van Nieuwenhuysen, et al.. (2023). Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI. International Journal of Gynecological Cancer. 33(12). 1890–1897. 1 indexed citations
6.
Engelhardt, Ellen G., Mignon D J M van Gent, Constantijne H. Mom, et al.. (2022). Psychological impact of referral to an oncology hospital on patients with an ovarian mass. International Journal of Gynecological Cancer. 33(1). 74–82. 2 indexed citations
7.
Vandecaveye, Vincent, Raphaëla C. Dresen, Els Van Nieuwenhuysen, et al.. (2022). 2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A273–A274. 1 indexed citations
8.
Jaeghere, Emiel A. De, Sandra Tuyaerts, Ann Belmans, et al.. (2022). 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial. International Journal of Gynecological Cancer. 32. A187–A188.
9.
Annibali, Daniela, et al.. (2021). Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers. 13(9). 2040–2040. 6 indexed citations
10.
Janssen, Julie M., Kristel Van Calsteren, Thomas P. C. Dorlo, et al.. (2021). Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clinical Pharmacokinetics. 60(6). 775–784. 18 indexed citations
11.
Lok, Christianne, Ekaterina S. Jordanova, Hugo M. Horlings, et al.. (2020). The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 477(4). 535–544. 8 indexed citations
12.
Boere, Ingrid, Christianne Lok, Tineke Vandenbroucke, & Frédéric Amant. (2017). Cancer in pregnancy: safety and efficacy of systemic therapies. Current Opinion in Oncology. 29(5). 328–334. 19 indexed citations
13.
Depreeuw, Jeroen, Ellen Stelloo, Elisabeth M. Osse, et al.. (2017). Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research. 23(23). 7232–7241. 35 indexed citations
14.
Church, Dawn R., Ellen Stelloo, Nadejda Valtcheva, et al.. (2014). PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER. Data Archiving and Networked Services (DANS).
15.
Church, David N., Ellen Stelloo, Remi A. Nout, et al.. (2014). Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. JNCI Journal of the National Cancer Institute. 107(1). 402–402. 241 indexed citations
16.
Loibl, Sibylle, et al.. (2014). Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy - Reply. Journal of Clinical Oncology. 32(3). 255–256. 1 indexed citations
17.
Floris, Giuseppe, Sileny Han, & Frédéric Amant. (2014). Pregnancy-associated breast cancer. SHILAP Revista de lepidopterología. 2 indexed citations
18.
Vandenput, Ingrid, Jone Trovik, Karin Leunen, et al.. (2011). Evolution in Endometrial Cancer. International Journal of Gynecological Cancer. 21(2). 316–322. 23 indexed citations
19.
Deprez, Sabine, Frédéric Amant, Ann Smeets, et al.. (2011). Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation With Impaired Cognitive Functioning. Journal of Clinical Oncology. 30(3). 274–281. 298 indexed citations
20.
Huang, Huei‐Jean, M. Drijkoningen, Robert Paridaens, et al.. (2005). Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of Clinical Pathology. 58(6). 611–616. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David M. Gershenson Breakdown of academic impact, for papers by David G. Mutch Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Robert L. Coleman Breakdown of academic impact, for papers by Hys Ngan Breakdown of academic impact, for papers by Michael Friedländer Breakdown of academic impact, for papers by Jonathan S. Berek Breakdown of academic impact, for papers by Ursula A. Matulonis Breakdown of academic impact, for papers by Stephen C. Rubin Breakdown of academic impact, for papers by Douglas A. Levine
Rankless by CCL
2026